Novartis (NOVN SW) is to add radioligand therapy manufacturing facility within Florida. Advancing USD 23bln investment projected announced in April 2025.

Novartis (NOVN SW) is to add radioligand therapy manufacturing facility within Florida. Advancing USD 23bln investment projected announced in April 2025.

Novartis is expanding its operations with a new manufacturing facility in Florida, which is part of a significant $23 billion investment first announced in April 2025. This strategic move not only enhances its production capabilities in the growing radioligand therapy market but also highlights its commitment to expanding its footprint in the lucrative U.S. healthcare sector. Investors may view this expansion as a positive signal for Novartis’ long-term growth potential and might impact sentiment in related sectors such as pharmaceuticals and biotechnology.